SupplySide West Review: Embria Presents New Research on EpiCor’s Immune Effects on Gut Health

November 20, 2012

The study used a multistage simulator of the human digestive system.

Stuart Reeves, PhD, director of research and health for Embria Health Sciences (Ankeny, IA), gave a VendorBrief presentation discussing the results of an in vitro study involving the company’s EpiCor ingredient and immune effects on gut health. The study used a multistage simulator of the human digestive system. Through this advanced research model, the company was able to ascertain a variety of mechanisms by which EpiCor supports gut health.

Specifically, it says, EpiCor acts as a prebiotic, which may explain its effects as an immune modulator. The study also showed that EpiCor significantly increased the levels of butyrate. Butyrate is a short-chain fatty acid that has been shown to benefit gut immune health. Additionally, EpiCor was shown to significantly increase the levels of beneficial bacteria (Bifidobacteria and Lactobacilli) compared with control.

Levels of secretory IgA also increased with EpiCor versus placebo. IgA is a vital immunoglobulin present in mucosal membranes and is the body’s first line of defense against pathogens.